{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78"}]}],"title":"Any AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27"}]}],"title":"Any SAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in other situations.","groups":[{"description":"Participants received pazopanib 800 milligrams (mg) once daily.","id":"OG000","title":"Pazopanib 800 mg"}],"paramType":"NUMBER","populationDescription":"All Treated Participants (ATP) Population: all enrolled participants who received at least one dose of open-label investigational product","reportingStatus":"POSTED","timeFrame":"From Baseline to Follow-up (up to 6.230 years)","title":"Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)","type":"PRIMARY","unitOfMeasure":"participants"}